Roche Holding AG (SWX: RO)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 225.72B |
| Revenue (ttm) | 60.58B |
| Net Income (ttm) | 10.62B |
| Shares Out | n/a |
| EPS (ttm) | 13.24 |
| PE Ratio | 21.26 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Mar 14, 2024 |
| Volume | 14,430 |
| Average Volume | 20,238 |
| Open | 295.00 |
| Previous Close | 299.40 |
| Day's Range | 293.60 - 304.00 |
| 52-Week Range | 229.40 - 312.00 |
| Beta | 0.15 |
| RSI | 71.57 |
| Earnings Date | Jan 31, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, d... [Read more]
Financial Performance
In 2023, Roche Holding AG's revenue was 60.44 billion, a decrease of -8.16% compared to the previous year's 65.81 billion. Earnings were 11.50 billion, a decrease of -7.43%.
Financial StatementsNews
Roche CEO: We had a strong 2024 and expect momentum to carry into 2025
Thomas Schinecker, the CEO of Roche, discusses the Swiss company's full-year earnings.
We had a strong 2024 and expect momentum to carry into 2025, says Roche CEO
Thomas Schinecker, the CEO of Roche, discusses the Swiss company's full-year earnings.
Roche Holding Non-GAAP EPS of CHF 18.80, revenue of CHF 60.49B
Roche sees high single-digit core profit growth in 2025
Swiss drugs and diagnostics company Roche said on Thursday it is targeting an increase in core 2025 earnings per share in a high single-digit percentage range, when adjusted for currency swings.
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
Basel, 30 January 2025 Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics. Excluding COVID-19, Group sales increased by 9%.
Change to the Roche Enlarged Corporate Executive Committee
Basel, 29 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company as Chief Digital Technology Officer (CDTO), reporting to Group CEO, Thomas S...
Genentech's Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
– Updated overall survival (OS) results – a key secondary endpoint – reinforce the significant benefit of the Itovebi TM (inavolisib)-based regimen for patients with advanced PIK3CA-mutated, HR-positi...
Roche's Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer
Basel, 28 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from the overall survival (OS) analysis of the phase III INAVO120 study investigating ItovebiTM (in...
Genentech's Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the overall survival (OS) analysis of t...
Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)
Basel, 27 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from year two of the EMBARK trial, a global, randomised, double-blind phase III study of Elevidys™ ...
Roche gets FDA clearance for STI test panels
Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care
Basel, 22 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance and Clinical Laboratory Improvement Amendments...
Roche descendant André Hoffmann on pharma, feuds and family business
Davos trustee and ESG backer takes stand against ‘arrogance’ of Trump and Musk
B-cell Depletion Innovation Research Report 2024: Roche Dominate the Patent Activity in B-cell Depletion Therapy, with a Dip in New Companies Filing Patents in Recent Years
Dublin, Jan. 17, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: B-cell Depletion" report has been added to ResearchAndMarkets.com's offering.
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
On Thursday, Outlook Therapeutics, Inc. (NASDAQ: OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular degene...
Dyno Therapeutics Announces Exercise of Option by Roche for Next-Generation AAV Vector for Neurological Gene Therapy
WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics announces exercise of option by Roche for next-generation AAV vector for neurological gene therapy.
Roche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma
The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation (ISH) test with the sensitivity to assess the full spectrum of B-cell lymphoma su...
Danielle Dysinger: Engineering Creativity, Advocacy, and the Great Outdoors
Danielle Dysinger is an engineer, entrepreneur, and passionate advocate based in Tucson, Arizona. A graduate of the University of Arizona with a degree in chemical engineering, Danielle has built a dy...
Roche Finalizes Poseida Acquisition: This Cell Therapy Deal Feels Like A Win/Win
Roche's momentum in digital pathology continues with FDA clearance on its high-volume slide scanner
The VENTANA DP 600 slide scanner, part of Roche's Digital Pathology Dx system, is now cleared by the FDA to aid in clinical diagnosis, enabling pathologists to diagnose patients using digital images. ...
Roche to close $1.5B acquisition of Poseida Therapeutics
Discover the latest news and updates on Roche Diagnostics with insights on their Silicon Valley campus facade.
Roche to complete acquisition of U.S. biopharma company Poseida
Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics via its subsidiary Blue Giant Acquisition Corp.
Roche purchases shares in tender offer for Poseida Therapeutics, Inc.
Basel, 8 January 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche's wholly owned subsidiary Blue Giant Acquisition Corp. has accepted for payment all shares validly tendered and no...
Roche Vabysmo Sales Surpassed USD 4 Billion In 2024
Vabysmo Sales Accounts For More Than 35% Of Global Bispecific Antibodies Market Says Kuick Research Vabysmo Sales Accounts For More Than 35% Of Global Bispecific Antibodies Market Says Kuick Research
Roche Executing Commercially, But R&D Productivity Remains A Work In Progress
Roche Executing Commercially, But R&D Productivity Remains A Work In Progress